DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60 Day–06–0425X]

Proposed Data Collections Submitted for Public Comment and Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call 404–639–5960 and send comments to Seleda Perryman, CDC Assistant Reports Clearance Officer, 1600 Clifton Road, MS–D74, Atlanta, GA 30333 or send an e-mail to omb@cdc.gov.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Written comments should be received within 60 days of this notice.

Proposed Project


Background and Brief Description

The Children’s Health Act of 2000 mandated CDC to establish autism surveillance and research programs to address the number, incidence, correlates, and causes of autism and related disabilities. Under the provisions of this act, CDC funded 5 CADDRE centers including the California Department of Health and Human Services, Colorado Department of Public Health and Environment, Johns Hopkins University, the University of Pennsylvania, and the University of North Carolina at Chapel Hill. CDC National Center on Birth Defects and Developmental Disabilities will participate as the 6th site. The multi-site, collaborative study will be an epidemiological investigation of possible causes for the autism spectrum disorders.

Study participants will be selected from children born in and residing in the following six areas: Atlanta metropolitan area, San Francisco Bay area, Denver metropolitan area, Baltimore metropolitan area, Philadelphia metropolitan area, and Central North Carolina. Children with autism spectrum disorders will be compared to children with other developmental problems, referred to as the neurodevelopmentally impaired group (NIC), as well as children who do not have developmental problems, referred to as the subcohort.

Data collection methods will consist of the following: (1) Medical record review of the child participant; (2) medical record review of the biological mother of the child participant; (3) a packet sent to the participants with self-administered questionnaires and a buccal swab kit; (4) a telephone interview focusing on pregnancy-related events and early life history (biological mother and/or primary caregiver interview); (5) a child development evaluation (more comprehensive for case participants than for the control group participants); (6) parent-child development interview (for case participants only) administered over the telephone or in-person; (7) a physical exam of the child participant; (8) biological sampling of the child participant (blood and hair); and (9) biological sampling of the biological parents of the child participant (blood only). There is no cost to respondents other than their time.

ESTIMATED ANNUALIZED BURDEN HOURS

<table>
<thead>
<tr>
<th>Form</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Avg. burden per response (in hours)</th>
<th>Total burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Initial Contact by Mail</td>
<td>17,610</td>
<td>1</td>
<td>0.17</td>
<td>2,994</td>
</tr>
<tr>
<td>2. Invitation Telephone Contact</td>
<td>8,922</td>
<td>1</td>
<td>0.33</td>
<td>2,944</td>
</tr>
<tr>
<td>3. Self-administered Questionnaires and buccal sample</td>
<td>3,456</td>
<td>1</td>
<td>3.17</td>
<td>10,955</td>
</tr>
<tr>
<td>4. Caregiver Interview by telephone</td>
<td>3,282</td>
<td>1</td>
<td>0.83</td>
<td>2,724</td>
</tr>
<tr>
<td>5. Child Clinic Visit (Child Development Evaluation, physical exam, and biosamples)</td>
<td>3,114</td>
<td>1</td>
<td>2.0</td>
<td>1,620</td>
</tr>
<tr>
<td>Case</td>
<td>810</td>
<td>1</td>
<td>1.33</td>
<td>1,556</td>
</tr>
<tr>
<td>NIC</td>
<td>1,170</td>
<td>1</td>
<td>1.33</td>
<td>1,508</td>
</tr>
<tr>
<td>Subcohort</td>
<td>1,134</td>
<td>1</td>
<td>1.33</td>
<td>1,508</td>
</tr>
<tr>
<td>6. Parent-Child Development Interview (Case participants only)</td>
<td>810</td>
<td>1</td>
<td>3.17</td>
<td>2,568</td>
</tr>
<tr>
<td>7. Parent biosamples</td>
<td>3,114</td>
<td>1</td>
<td>0.25</td>
<td>779</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td>27,648</td>
</tr>
</tbody>
</table>
DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Notice of Charter Renewal

This gives notice under the Federal Advisory Committee Act (Pub. L. 92–463) of October 6, 1972, that the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel, Centers for Disease Control and Prevention, Department of Health and Human Services, has been renewed for a 2-year period through September 18, 2008.

For information contact Elaine L. Baker, Designated Federal Officer, Disease, Disability, and Injury Prevention and Control Special Emphasis Panel, Centers for Disease Control and Prevention, Management Analysis and Services Office, 1600 Clifton Road, NE, Mailstop E72, Atlanta, Georgia 30333, telephone 404–498–0090 or fax 404–498–0011.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.


Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E6–16464 Filed 10–4–06; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Discontinued Publication of Funding Opportunity Announcements

AGENCY: The Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of New Procedure.

Important notice regarding: (1) Discontinued publication of Funding Opportunity Announcements (FOAs) in the Federal Register; and (2) FOA announcement and application submission via Grants.gov. CDC announces plans to publish all FOAs on http://www.grants.gov and accept electronic applications through this site. All application packages will be posted on Grants.gov, as well, utilizing the PHS5161–1 forms for non-research applications and the new form SF 424 Research and Related (R&R) application for research. Grants.gov will feed the form 424 (R&R) packages directly into the Health and Human Services electronic Research Administration Commons for on-line receipt of research applications.

As of October 1, 2005, CDC ceased publication of all FOAs in The Federal Register. CDC currently announces these FOAs, also known as Requests for Application (RFAs) and Program Announcements (PAs), via the Grants.gov on-line submission system. Applicants are able to find a synopsis and attachments of the complete text of all CDC grants and cooperative agreements, as well as apply electronically for opportunities, via http://www.Grants.gov. All FOAs will continue to be posted on the CDC Web site (http://www.cdc.gov/od/pgo/funding/FOAs.htm) and on the NIH Guide (http://grants1.nih.gov/grants/guide/index.html), for research.

The provisions of the Federal Financial Assistance Management Improvement Act of 1999 (Public Law 106–107) and the President’s Management Agenda have led Federal Agencies to simplify Federal financial assistance application requirements and create a single Web site to apply for Federal assistance. Accordingly, Grants.gov (http://www.grants.gov/) has been designated by the Office of Management and Budget (OMB) as the single access point for all grant programs offered by 26 Federal grant-making agencies. It provides a single interface for agencies to announce their grant opportunities, and for all grant applicants to find and apply for these opportunities.

The PHS–5161–1 application package will be posted in Grants.gov for CDC non-research application submissions. A transition from the PHS Form 398 package to the SF 424 (R&R) forms will allow electronic submission of research applications through Grants.gov.

Getting Started—Grants.gov and HHS eRA Commons Registration

To provide a secure environment, the submission of electronic applications to HHS and CDC will require organizations to register with Grants.gov (http://www.grants.gov/applicants/applicants.jsp), and, in addition, for Research Grants, the applicant will also have to register with HHS eRA Commons (https://commons.era.nih.gov/commons/). Grants.gov registration provides the ability to submit applications electronically to at least 26 Federal grant-making agencies. HHS eRA Commons registration allows tracking of research application status for the potential grantee organization and Principal Investigator.

Additional Information

Questions regarding this notice should be directed to the Technical Information Management Section (TIMS), Procurement and Grants Office, Centers for Disease Control and Prevention, 2920 Brandywine Road, Atlanta, GA 30341, Telephone 770–488–2700, or e-mail address: pgotim@cdc.gov.

Dated: September 26, 2006.

James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.

[FR Doc. E6–16322 Filed 10–4–06; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Request for Nominations for Nonvoting Members Representing Industry Interests on Public Advisory Panels or Committees

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for nonvoting industry representatives to serve on the National Mammography Quality Assurance Advisory Committee (NMQAAC) and certain device panels of the Medical Devices Advisory Committee in the Center for Devices and Radiological Health.

DATES: Industry organizations interested in participating in the selection of a nonvoting member to represent industry for the vacancies listed in this document must send a letter to FDA by November 6, 2006, stating their interest in the NMQAAC or one or more panels. Concurrently, nomination materials for prospective candidates should be sent to FDA by November 6, 2006. A nominee